Apnimed(NASDAQ) APMD

Apnimed, Inc. makes pills for people with sleep breathing problems. These oral drugs help keep airways open during the night. The company aims to replace bulky machines for sleep apnea.

Moving Beyond Breathing Machines

• Oxnimbi (AD109): Investigational oral pill designed to treat obstructive sleep apnea by improving airway muscle activity.
• Neuromuscular Modulator: Combination therapy that targets muscle dysfunction to prevent airway collapse during sleep.
• Phase 3 Trials: Clinical programs known as LunAIRo and SynAIRgy that enrolled approximately 1,300 patients.

Deals, Dates, and New Dollars

• Submitted a New Drug Application to the FDA for Oxnimbi in April 2026.
• The FDA assigned a Prescription Drug User Fee Act goal date of Feb. 28, 2027.
• Sold its interest in a joint venture to Shionogi for $100 million in April 2026.
• Secured a credit agreement providing up to $150 million in term loans in April 2026.
• Completed an initial public offering in Aug. 2026, raising approximately $200.4 million.

A New Approach to Sleep

Apnimed focuses on treating the neurobiology of sleep apnea instead of using mechanical hardware. Its clinical trials created one of the largest data sets for pharmacological treatments in this field.

Record Gains and Growing Reserves

• Revenue from related parties was $96.9 million for the six months ended June 30, 2026, up 379% year over year.
• Net income reached $193.7 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents totaled $172.8 million as of June 30, 2026.
• The company recorded an $85.4 million gain on the sale of an investment in April 2026.
• Operating expenses for the six months ended June 30, 2026, were $40.6 million.

The Road to Commercialization

Apnimed has evolved from a private research firm to a clinical company with a pending FDA application. Its strategy relies on monetizing early partnerships while building independent commercial infrastructure for its lead sleep apnea pill.